Sanofi Signs an Exclusive Agreement with Roche for OTC Rights of Tamiflu (oseltamivir phosphate) in the US

Sanofi Signs an Exclusive Agreement with Roche for OTC Rights of Tamiflu (oseltamivir phosphate) in the US

Shots:

  • Sanofi will lead FDA negotiations for the OTC switch, marketing and distribution of Tamiflu OTC and will be responsible for clinical programs and fund all studies needed to support OTC switch in the US. Sanofi will retain the right to switch the first negotiation in other selected markets
  • Roche will retain the right to commercialize Tamiflu in the rest of the world for the treatment of influenza or flu
  • Tamiflu is an antiviral therapy indicated for the treatment of influenza in patients aged 2wks. and older with flu symptoms for no more than 2 days and reduces the chance of getting the flu in people with 1 year and older

Click here to read full press release/ article | Ref: Sanofi | Image: GMP News